Dengue Testing Market

Global Dengue Testing Market Size (2023 to 2028)

The global market size for dengue testing is predicted to be growing at a CAGR of 6.02% from 2023 to 2028 and be worth USD 927.4 million by 2028 from USD 692.3 million in 2023.

The dengue virus is transmitted by biting female mosquitos of the aegypti that dwell in tropical and subtropical regions. The symptoms of dengue are high fever, vomiting, skin rashes, severe muscle and joint pain, severe headache, and bleeding of the nose or gums. Health complications due to severe dengue have caused severe illness and death. According to the world health organization, on 2022 Feb 7, there were 40,154 cases registered across the Americas and the Caribbean, with 7873 confirmed cases and nine associated deaths. In addition, the reported countries such as Colombia (3,182), Brazil (29,886), Mexico (1065), Peru (4247), and Paraguay (967).  The dengue fever surveillance indicators are at low levels or even zero in the French Antilles, such as Martinique, Guadeloupe, Saint-martin, and Saint-Barthelemy). On the other hand, south Asian countries are more prone to Dengue prevalence. 

Impact of COVID-19 on the global dengue testing market:

The global pandemic SARS-COV-2 has significantly impacted the dengue testing market. The disease frequency was relatively high, and it spread to countries worldwide. As a result, the dengue testing market suffered since the government's principal focus was combating COVID-19. However, the symptoms of the Dengue virus and the virus that causes the COVID-19 virus are identical in the early stages. As a result, most individuals confuse dengue when they get tested for dengue. However, according to an article published in the Journal of Medical Virology in March 2021, the number of dengue infections in the country is increasing, requiring urgent public initiatives to combat the disease.

MARKET DRIVERS:

The growing number of dengue cases worldwide and changing climatic conditions propelled the dengue testing market growth.

Dengue fever has been on the rise at an alarming rate in recent decades, raising concerns among medical professionals. Dengue virus transmission has been aided by changing weather conditions and unsuitable habitats. However, the increased frequency of dengue fever has sent shockwaves across the global dengue testing market, particularly in developing nations. Africa, America, the Eastern Mediterranean, Southeast Africa, and the Western Pacific have seen the highest dengue cases over the forecast period.

On the other hand, climatic change in emerging countries has considerably impacted vector dispersion and possible disease transmission. High rainfall increases the number of breeding places; however, humidity affects mosquito longevity, influencing market growth. Technological advancements in the healthcare sector and the growing adoption of advanced healthcare services and treatments boost the market. As a result, the demand within the global market for dengue testing has been rising at an unprecedented rate, majorly due to advancements in the field of healthcare diagnostics.

In addition, the increasing R&D activities on the creation of highly specific and sensitive diagnostics kits are expected to offer significant market growth opportunities. Furthermore, flavivirus research has accelerated over the last decade, and this aspect is projected to drive significant growth to the worldwide dengue testing market. In emerging countries such as the U.S., France, and China, manufacturers focus on developing point-of-care testing, which is rapid, sensitive, and convenient, and expected to accelerate market growth. Furthermore, increasing initiatives and funding by the government for creating awareness programs through medical tourism is positively influencing the market demand. In addition, the presence of trained medical professionals and technicians could aid the growth of the global dengue testing market.

MARKET RESTRAINTS:

However, the high cost of dengue testing and limited access to healthcare services in underdeveloped countries limit market growth. 

REPORT COVERAGE:

This research report on the global dengue testing market has been segmented and sub-segmented based on the product, end-user, and region.

Global Dengue Testing Market – By Product:

• ELISA-based Tests
• RT-PCR-based Tests
• Dengue IgG/IgM Rapid Test

Based on the product, the RT-PCR-based tests segment accounted for the largest share of the global dengue testing market in 2022. On the other hand, the ELISA-based tests segment is predicted to account for a sizable share over the forecast period. The (ELISA) test is one of the most extensively used and accepted procedures for diagnosing dengue. ELISA is the usual approach for detecting NS1 antigens and differentiating the four dengue virus serotypes. Therefore, ELISA has become the preferred diagnostic method when a laboratory with trained workers and equipment is available.

Global Dengue Testing Market – By End-User:

• Hospitals
• Public Health Laboratory 
• Diagnostic centers  
• Others 

Based on the End-user, the hospital segment accounted for the largest share of the market, and it is anticipated to record a significant share during the forecast period. The segment growth is driven by the increasing prevalence of dengue patients, improving hospital infrastructure, and the availability of testing kits. 

Global Dengue Testing Market – By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Geographically, the Asia Pacific dominated the global dengue testing market in 2022 and is projected to be the most attractive regional market for dengue testing across the world. The APAC dengue testing market is also expected to register a record CAGR of 42.8% during the forecast period. The improving healthcare infrastructure, growing population, and favorable government policies contribute to regional market growth. Also, emerging countries such as China, Japan, and India are significantly contributing to APAC regional market. Furthermore, in certain areas, including Malaysia, the Philippines, and Vietnam, increasing government spending on improving healthcare facilities and a growing emphasis on carrying out dengue awareness campaigns have a beneficial impact on market growth.

China held a substantial share of the Asia Pacific regional market in 2022. The rising number of dengue cases, technological improvements in the healthcare sector, and high healthcare expenditure all contributed to a growing market. However, southern China has seen a high transmission frequency and recurring dengue outbreaks in recent years, particularly in Guangzhou, accounting for 69.2 percent of all recorded cases in mainland China. As a result, rising dengue incidences are likely to increase demand for diagnostic tests in the region, resulting in market growth in the coming future.

The Indian dengue testing market is expected to account for a sizable market share. The state's weak vector control, combined with the state's expanding population. Furthermore, the ground conditions in India this year have been ideal for a dengue outbreak - the country has seen a prolonged rainy season, which has allowed for other mosquito breeding places.

On the other hand, the North American market is projected to record a significant share of the global market during the forecast period. The regional market growth is attributed to advanced healthcare infrastructure, favorable reimbursement policies, and notable market players, and dengue outbreaks occasionally occur in the continental United States. Dengue is expected in the US territories of Puerto Rico, the US Virgin Islands, and American Samoa. Nearly all dengue cases reported in the 48 contiguous US states were in travelers infected elsewhere.

Europe is also expected to hold a considerable share of the global market due to expanding healthcare developments and rising risk factors of dengue virus infections caused by climate change.

KEY MARKET PARTICIPANTS:

Companies playing a leading role in the global dengue testing market profiled in this report are Thermo Fisher Scientific, Abbott Laboratories, Roche Molecular Systems, NovaTec Immundiagnostica, Abnova, OriGene Technologies, InBios International, Certest Biotec, PerkinElmer, and Quest Diagnostics.

RECENT HAPPENINGS IN THIS MARKET:

• Roche and GenMark Diagnostics entered into a definitive merger agreement in March 2021 for Roche to entirely acquire GenMark in an all-cash deal for USD 24.05 per share.
• In September 2021, CoSara Diagnostics Pvt Ltd announced receiving regulatory permission from the Central Drug Standard Control Organization (CDSCO) to produce and distribute the SARAGENE Dengue Test Kit. The SARAGENE Dengue Test Kit is an in vitro diagnostic test based on Real-Time Polymerase Chain Reaction Technology that employs Co-Diagnostics' unique CoPrimers technology.